Orthofix Medical Inc.OFIXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank59
3Y CAGR-26.3%
5Y CAGR+0.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-26.3%/yr
Quarterly compound
5Y CAGR
+0.0%/yr
Recent deceleration
Percentile
P59
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.05% |
| Q3 2025 | -7.28% |
| Q2 2025 | -19.39% |
| Q1 2025 | 5.09% |
| Q4 2024 | 8.75% |
| Q3 2024 | -4.18% |
| Q2 2024 | -7.40% |
| Q1 2024 | 2.91% |
| Q4 2023 | 2.06% |
| Q3 2023 | -4.45% |
| Q2 2023 | -16.66% |
| Q1 2023 | 77.21% |
| Q4 2022 | 10.12% |
| Q3 2022 | -6.39% |
| Q2 2022 | 13.79% |
| Q1 2022 | -15.34% |
| Q4 2021 | 7.14% |
| Q3 2021 | -5.80% |
| Q2 2021 | 20.41% |
| Q1 2021 | 5.13% |
| Q4 2020 | 4.05% |
| Q3 2020 | 13.66% |
| Q2 2020 | -12.03% |
| Q1 2020 | 17.97% |
| Q4 2019 | 5.81% |
| Q3 2019 | -11.11% |
| Q2 2019 | -2.70% |
| Q1 2019 | 4.97% |
| Q4 2018 | -8.40% |
| Q3 2018 | 21.63% |
| Q2 2018 | 13.75% |
| Q1 2018 | -17.94% |
| Q4 2017 | 21.90% |
| Q3 2017 | 0.70% |
| Q2 2017 | -7.23% |
| Q1 2017 | -1.13% |
| Q4 2016 | 9.49% |
| Q3 2016 | 0.97% |
| Q2 2016 | -11.05% |
| Q1 2016 | 0.87% |